Tonix Pharmaceuticals Holding Corp. (TNXP) Director Sells $35,700.00 in Stock
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Ernest Mario sold 10,000 shares of the stock in a transaction on Monday, December 18th. The shares were sold at an average price of $3.57, for a total value of $35,700.00. Following the sale, the director now owns 10,000 shares of the company’s stock, valued at approximately $35,700. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Ernest Mario also recently made the following trade(s):
- On Thursday, December 14th, Ernest Mario sold 1,967 shares of Tonix Pharmaceuticals stock. The shares were sold at an average price of $3.58, for a total value of $7,041.86.
- On Thursday, December 21st, Ernest Mario sold 36,967 shares of Tonix Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $129,754.17.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) opened at $3.52 on Monday. The stock has a market capitalization of $26.91, a price-to-earnings ratio of -0.74 and a beta of 2.92. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $2.85 and a 52 week high of $9.40.
An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Vanguard Group Inc. raised its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 184,377 shares of the company’s stock after buying an additional 41,264 shares during the period. Vanguard Group Inc. owned about 2.46% of Tonix Pharmaceuticals worth $799,000 at the end of the most recent quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/25/tonix-pharmaceuticals-holding-corp-tnxp-director-sells-35700-00-in-stock.html.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.